Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-23T14:32:57.578Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparison of Bromocriptine (Parlodel®) and Levodopa-Carbidopa (Sinemet®) For Treatment of “De Novo” Parkinson's Disease Patients

Published online by Cambridge University Press:  18 September 2015

Israel Libman ,
Marek J. Gawel ,
Richard J. Riopelle  and
Sylvie Bouchard
Israel Libman
Affiliation:
Jewish General Hospital, Montreal
Marek J. Gawel
Affiliation:
Sunnybrook Hospital, Toronto
Richard J. Riopelle
Affiliation:
Kingston General Hospital, Kingston
Sylvie Bouchard*
Affiliation:
Sandoz Canada Inc
*
Chef du Groupe Système Nervcux Central, Direction Scientifique, Laboratoires Sandoz France Ltée, 14, Boulevard Richelieu, BoÎte postale 313, 92508 Rueil Malmaison Cedex, France
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Fifty-one patients were enrolled in a double-blind, parallel group, multicentre study conducted to assess short-term efficacy and tolerance of bromocriptine (Parlodel®) or L-DOPA/carbidopa (Sinemet®) in patients never treated with amantadine, ergot alkaloids or L-DOPA-based drugs. An attempt to use the lowest effective dose was made. The responder rate for each group was approximately 78%; the mean daily dose for responders was 22.5 mg of bromocriptine or 250 mg of L-DOPA/carbidopa. The overall clinical improvement in each group was 62% (bromocriptine) and 55% (L-DOPA/carbidopa) for neurological assessment and 36% (bromocriptine) and 31% (L-DOPA/carbidopa) for functional disability. Comparison between groups did not show any significant difference for both neurological and disability assessments. The most frequent side effect was nausea (L-DOPA, N = 3; bromocriptine, N=6).

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue 4 , November 1987 , pp. 576 - 580
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

1.Calne, DB, Teychenne, PF. Claveria, LE, et al. Bromocriptine in Parkinsonism. Brit Med J 1974; 4: 442–4.CrossRefGoogle ScholarPubMed
2.Grimes, D, Hassan, MN. Method of addition of bromocriptine to the drug regimen of patients with advanced Parkinson’s disease. Can J Neurol Sci 1981; 8(1): 31–4.CrossRefGoogle Scholar
3.Meco, G, Casacchia, M. Zamponi, A, et al. CB154 in the treatment of Parkinson’s disease. Atti della 3e riunione lega Ital Contro M Parkinson/Mal Extrapiram. Ban9-IOX. 1976: 340–7.Google ScholarPubMed
4.Molina-Negro, P, Grimes, JD. Jones, MW, et al. Bromocriptine (Parlodel1) in the treatment of Parkinson’s disease. Prog Neuro-Psycho Pharmacol & Biol Psychiat 1982: 6: 503–8.CrossRefGoogle ScholarPubMed
5.Parkes, JD. Bromocriptine in the treatment of Parkinsonism. Drugs 1979; 17: 365–382.CrossRefGoogle ScholarPubMed
6.Markham, CH, Diamond, SG. Long-term follow-up of early dopatreatment in Parkinson’s disease. Ann Neurol 1986: 365–72.CrossRefGoogle ScholarPubMed
7.Jenner, P, Boyce, S, Marsden, CD. Effect of repeated L-DOPA administration on striatal dopamine receptor function in the rat. Recent Developments in Parkinson’s Disease, edited by Fahn, S.et al. Raven Press. New York. 1986; 189–203.Google Scholar
8.Marsden, CD, Parkes, JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet. 1976: 1: 292–5.CrossRefGoogle ScholarPubMed
9.Rinne, UK. Brain dopamine receptors in Parkinson’s disease: Involvement with clinical features and therapeutic responses. In: Human brain tissue. Reiderer, P. & Usdin, E., eds., Macmillan Press Ltd., 1982.Google Scholar
10.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson’s disease — clinical aspects. Movement Disorders. Marsden, CD. and Fahn, S., eds. Butterworth Scientific, London. 1982: 96–122.Google Scholar
11.Hoehn, M. Bromocriptine and its use in Parkinsonism. J Am Geriatrics Soc 1981; 29(6): 251–8.CrossRefGoogle ScholarPubMed
12.Lees, AJ, Stern, GM. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. Adv in Neurol Experim Therof Mov Disor, Fahn, S., Calne, D.B. and Shoulson, I., eds. Raven Press. N.Y.. 1983; 37: 17–21.Google Scholar
13.LeWitt, PA, Calne, DB. Recent advances in the treatment of Parkinson’s disease: The role of bromocriptine. N Neural Transmission 1981; 51: 175–184.CrossRefGoogle Scholar
14.Lieberman, A. Kupersmith, M, Neophytides, A. et al. Long-term efficacy of bromocriptine in Parkinson’s disease. Neurology 1980; 30(5): 518–523.CrossRefGoogle Scholar
15.Godwin-Austen, RB. Aspects ofbromocriptine therapy in Parkinson’s disease. Res & Clin Forums 1981; 3(2): 19–27.Google Scholar
16.Teychenne, PF, Bergsrud, D, Elton, RL, et al. Bromocriptine: longterm low dose therapy in Parkinson’s disease. Clin Neurophar-macol 1986; 9: 138–45.CrossRefGoogle ScholarPubMed
17.Rascol, A, Guiraud, B, Montastruc, JL, et al. Long-term treatment of Parkinson’s disease with bromocriptine. J Neurol Neurosurg — Psychiatry 1979; 42: 143–150.CrossRefGoogle ScholarPubMed
18.Corrodi, H, Fuxe, K, Hokfelt, T, et al. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J of Pharmacy and Pharmacology 1973; 25: 409–12.CrossRefGoogle ScholarPubMed
19.Goldstein, M, Lew, JY, Nakamura, S, et al. Dopaminophilic properties of ergot alkaloids. Fed Proc 1978: 37: 2202–5.Google ScholarPubMed
20.Calne, DB. Burton, K, Beckman, J, et al. Dopamine agonists in Parkinson’s disease. Can J Neurol Sci 1984; 11: 221–4.CrossRefGoogle ScholarPubMed
21.Rinne, UK. Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 1985: 35: 1196–8.CrossRefGoogle ScholarPubMed
22.Calne, DB, Williams, AC, Nutt, JG, Neophytides, A, Teychenne, PF. Ergot derivatives for Parkinsonism. Med J Austr Spec Suppl 1978; 2(3): 25–6.CrossRefGoogle ScholarPubMed
23.Hoehn, MM, Yahr, MD. Parkinsonism onset progression and mortality. Neurology 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
24.Duvoisin, RC. The evaluation of extra-pyramidal disease. In: de Ajuriagerra, J., ed. Monoamines: noyaux gris centraux et syndrome de Parkinson. Paris: Masson 1970; 313–25.Google Scholar
25.Canter, JC, de La Torre, R, Mier, M. A method for evaluating disability in patients with Parkinson’s disease. N Nerv Ment Dis 1961; 7: 133–43.Google Scholar
26.Winer, BJ. Statistical principles in experimental design. New York: McGraw Hill, 2nd edition, 1971.Google Scholar
27.Bailey, BJR. Tablesof the Bonferroni t statistics. J.A.S.A. 1977: 72: 469–77.Google Scholar
28.Teychenne, PF. Bergsrud, DW, Racy, A. Long-term effectiveness of low-dose bromocriptine in Parkinson disease. Neurology (NY) 1982; 32(2) A181.CrossRefGoogle Scholar
29.Staal-Schreinemachers, AL, Wesseling, H, Kamphuis, DJ, et al. Low-dose bromocriptine therapy in Parkinson’s disease: Double-blind, placebo-controlled study. Neurology 1986: 36: 291–3.CrossRefGoogle ScholarPubMed
30.Grimes, JD, King, DB, Kofman, OS, Molina-Negro, P, Wilson, AF, Bouchard, S. Bromocriptine in the management of end of dose deterioration in Parkinson’s disease. Can J Neurol Sci 1984; 11: 452–6.CrossRefGoogle ScholarPubMed
31.Lees, AJ, Haddad, S, Shaw, KM, Kohout, LF, Stern, GMI. Bromocriptine in Parkinsonism: A long-term study. Arch Neurol 1978; 35: 503–5.CrossRefGoogle ScholarPubMed
32.Stern, GM, Lees, AJ, Shaw, KM, Landry, CM. The role of bromocriptine treatment in Parkinson’s disease. Ergot Compounds and Brain function. Ed. by Goldstein, M.et al. Raven Press N.Y. 1980: 267–70.Google Scholar
33.Grimes, JD, Delgado, MR. Bromocriptine: Problems with low-dose de novo therapy in Parkinson’s disease. Clin Neuropharmacol 1985; 8: 73–7.CrossRefGoogle ScholarPubMed
34.Quinn, N, Illas, A, Lhermitte, F, Agid, Y. Bromocriptine and domperidone in the treatment of Parkinson’s disease. Neurology 1981; 31: 662–7.CrossRefGoogle Scholar